丁酸梭菌CGMCC 0313.1改善精神分裂症患者代谢综合征的临床结局。
Clostridium butyricum CGMCC 0313.1 improves clinical outcomes of metabolic syndrome in schizophrenic patients.
作者信息
Song Libin, Zhang Zhihua, Zheng Wenyan, Wang Yiqi, Zhang Yingzi
机构信息
Department of Pharmacy, The Third Hospital of Quzhou Quzhou 324002, Zhejiang, China.
出版信息
Am J Transl Res. 2025 Jun 15;17(6):4399-4408. doi: 10.62347/DNIL9369. eCollection 2025.
OBJECTIVE
To primarily analyze the therapeutic effectiveness of CGMCC 0313.1 (CB0313.1) in managing metabolic syndrome (MS) in patients with schizophrenia.
METHODS
A total of 100 schizophrenic patients with relatively stable conditions admitted were selected. Patients receiving CB0313.1 were assigned to the observation group (n=52), and the others undergoing lifestyle interventions without CB0313.1 were formed the control group (n=48). Additionally, changes in obesity indices, blood sugar (BS) data, lipid profiles, blood pressure (BP), oxidative stress markers, Positive and Negative Syndrome Scale (PANSS) scores, treatment efficacy, and quality of life were evaluated before and after 12 weeks of intervention.
RESULTS
After the intervention, the observation group presented significantly greater improvements in oxidative stress reduction, and overall therapeutic efficacy compared to the control group. In addition, the observation group showed more pronounced reductions in obesity indices, BS levels, lipid profiles, BP, and PANSS scores. However, improvements in quality-of-life were comparable between the two groups.
CONCLUSION
CB0313.1 helps enhance the clinical management of MS in schizophrenic patients.
目的
初步分析CGMCC 0313.1（CB0313.1）对精神分裂症患者代谢综合征（MS）的治疗效果。
方法
选取100例病情相对稳定的住院精神分裂症患者。接受CB0313.1治疗的患者被分配到观察组（n = 52），其余未接受CB0313.1而进行生活方式干预的患者组成对照组（n = 48）。此外，在干预12周前后评估肥胖指数、血糖（BS）数据、血脂谱、血压（BP）、氧化应激标志物、阳性和阴性症状量表（PANSS）评分、治疗效果及生活质量的变化。
结果
干预后，与对照组相比，观察组在减轻氧化应激及总体治疗效果方面有显著更大的改善。此外，观察组在肥胖指数、BS水平、血脂谱、BP及PANSS评分方面有更明显的降低。然而，两组在生活质量改善方面相当。
结论
CB0313.1有助于加强对精神分裂症患者MS的临床管理。
Zotero 插件